IN ASTHMA
CARE
PARTNER
IN ASTHMA
RELIEF
DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an
eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.
ASTHMA AS YOUNG AS 6 YEARSEXPLORE THE RESULTS
DUPIXENT IS NOT A STEROID OR AN IMMUNOSUPPRESSANT.1,a
aDupilumab is a dual inhibitor of IL-4 and IL-13 signaling. The mechanism of dupilumab action has not been definitively established.
DUPIXENT MAY OFFER
ASTHMA SYMPTOM RELIEF
TO YOUR APPROPRIATE
PATIENTS, INCLUDING:
Allergic asthma
patients with elevated
eosinophils
OCS-dependent asthma
patients—
DUPIXENT is the
only biologic indicated for
this patient
population1
Children (6+ years) with
moderate-to-
severe uncontrolled asthma
Patients with coexisting diseases, such
as atopic dermatitis or chronic
rhinosinusitis with
nasal polyposis1,2
Extensive clinical trial and real-world experience across indications
>6900 patients studied and >275K patients on therapy1,3,b
DUPIXENT has proven efficacy and a demonstrated safety profile in nearly 3000 patients with moderate-to-severe asthma1
b Data on File, Total US DUPIXENT Patients, data through August 12, 2022.
c ~72% of the total FEV1 improvement was seen at Week 2 with DUPIXENT 200 mg + SOC (n=264). Up to 470 mL improvement from baseline in pre-bronchodilator FEV1 at Week 52 with DUPIXENT 200 mg + SOC (n=264) vs 170 mL with placebo + SOC (n=148) (QUEST, EOS ≥300 cells/µL, secondary endpoint). 320 mL improvement from baseline in pre-bronchodilator FEV1 at Week 12 with DUPIXENT 200 mg + SOC (n=631) vs 180 mL with placebo + SOC (n=317) (LSM difference: 140 mL [95% CI: 80, 190 mL]) (QUEST, ITT population, primary endpoint). In QUEST, a significant difference from placebo + SOC was not observed at 12 weeks in change in pre-bronchodilator FEV1 in patients with baseline blood eosinophil levels <150 cells/µL taking DUPIXENT 200 mg + SOC.1
d A patient or caregiver may inject DUPIXENT after training in subcutaneous injection technique.1
Most Common
Adverse Reactions
The most common adverse reactions (incidence ≥1%) in patients with asthma
were injection site reactions, oropharyngeal pain, and
eosinophilia. In DRI12544 and QUEST, the
proportion of subjects who discontinued treatment
due to adverse events was 4% of the placebo + SOC
group, 3% of the DUPIXENT 200 mg Q2W + SOC
group, and 6% of the DUPIXENT 300 mg Q2W + SOC group.1
Trial Designs and Results
DRI12544: 24-WEEK STUDY–776 adults (≥18 years) with moderate-to-severe asthma on a standard of care of medium- or high-dose ICS and a long-acting beta agonist were randomized to either DUPIXENT 200 mg Q2We + SOC (n=150), DUPIXENT 300 mg Q2Wf + SOC (n=157), or placebo + SOC (n=158). Subjects enrolled in DRI12544 were required to have a history of 1 or more asthma exacerbations that required treatment with systemic corticosteroids or emergency department visit or hospitalization for the treatment of asthma in the year prior to trial entry. DUPIXENT was administered as an add-on to background asthma treatment. Primary endpoint: Mean change from baseline to Week 12 in FEV1 in patients with baseline eosinophils ≥300 cells/µL. Other endpoint: Annualized rate of severe exacerbation events during the 24-week treatment period.g Selected baseline demographics: Mean age: 49 years; female: 63%; White: 78%; mean duration of asthma: 22 years; mean exacerbations in previous year: 2.2; high-dose ICS use: 50%; pre-dose FEV1 at baseline: 1.84 L; mean FeNO: 39 ppb; mean total IgE: 435 IU/mL; and mean baseline blood eosinophil count: 350 cells/µL.1
QUEST: 52-WEEK STUDY–1902 adolescents (12-17 years) and adults (≥18 years) with moderate-to-severe asthma on a standard of care of medium- or high-dose ICS and a minimum of 1 and up to 2 additional controller medications were randomized into 2 groups: DUPIXENT 200 mg Q2We + SOC (n=631) or placebo + SOC (n=317); or DUPIXENT 300 mg Q2Wf + SOC (n=633) or placebo + SOC (n=321). Subjects enrolled in QUEST were required to have a history of 1 or more asthma exacerbations that required treatment with systemic corticosteroids or emergency department visit or hospitalization for the treatment of asthma in the year prior to trial entry. DUPIXENT was administered as add-on to background asthma treatment. Subjects with baseline blood eosinophil levels >1500 cells/μL (<1.3%) were excluded. Two primary endpoints: Annualized rate of severe exacerbation events during the 52-week treatment period in the overall population and mean change from baseline to Week 12 in FEV1 in the overall population. Selected secondary endpoint: Mean change from baseline to Week 52 in FEV1 in patients with different baseline levels of eosinophils. Selected baseline demographics: Mean age: 48 years; female: 63%; White: 83%; mean duration of asthma: 21 years; mean exacerbations in previous year: 2.1; high-dose ICS use: 52%; pre-dose FEV1 at baseline: 1.78 L; mean FeNO: 35 ppb; mean total IgE: 432 IU/mL; and mean baseline blood eosinophil count: 360 cells/µL.1
VENTURE: 24-WEEK STUDY–210 subjects (≥12 years) with asthma who required daily OCS in addition to regular use of standard of care of high-dose ICS and a minimum of 1 and up to 2 additional controller medications were randomized to receive either DUPIXENT 300 mg Q2Wf + SOC + OCS (n=103) or placebo + SOC + OCS (n=107). Subjects with baseline blood eosinophil levels >1500 cells/μL (<1.3%) were excluded. Primary endpoint: Percent reduction from baseline in OCS dose at Week 24, while maintaining asthma control, in the overall population. Other endpoints: Annualized rate of severe exacerbation events during the 24-week treatment period and mean change from baseline to Week 24 in FEV1. Selected baseline demographics: Mean age: 51 years; female: 61%; White: 94%; mean duration of asthma: 20 years; mean exacerbations in previous year: 2.1; high-dose ICS use: 89%; pre-dose FEV1 at baseline: 1.58 L; mean FeNO: 38 ppb; mean total IgE: 431 IU/mL; and mean baseline blood eosinophil count: 350 cells/μL.1,4
e With 400 mg loading dose.
f With 600 mg loading dose.
g Results were evaluated in the overall population and subgroups based on baseline blood eosinophil count.
PATIENT SYMPTOM
EVALUATION
QUESTIONNAIRE
Download the questionnaire for helpful questions
when evaluating your patients' asthma severity,
control, and referral eligibility.
Contact a Field Representative
Connect with a DUPIXENT Field Representative to get answers to your product-related questions.
Frequently asked questions about DUPIXENT
DUPIXENT is a biologic therapy and has a unique mechanism of action. DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling, inhibiting two key sources of type 2 inflammation in asthma. DUPIXENT is not an immunosuppressant or a steroid. The mechanism of dupilumab action has not been definitively established.1
SEE HOW DUPIXENT WORKSDUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.1
SEE THE EFFICACY AND SAFETY DATA OF DUPIXENT EXPLORE APPROPRIATE PATIENT TYPESDUPIXENT is typically prescribed by an asthma specialist, such as an allergist or a pulmonologist. If you have patients 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma who you think might be appropriate for DUPIXENT, consider referring them to an asthma specialist.1
For help finding aspecialist in your area,
use the HeaLthgrades® tool
Overall, ~98% of commercially insured patients nationally are covered for DUPIXENT.7,i Coverage varies by type and plan.
With the DUPIXENT formulary status tool, you can see which insurance plans offer coverage for DUPIXENT in your area. Contact the health plan or DUPIXENT MyWay® to verify coverage for a specific patient.
iMMIT Lives as of July 2022.
STATUS FOR DUPIXENT
IN YOUR AREA
For patients with a valid prescription for DUPIXENT, support is available through the DUPIXENT MyWay® patient support program. Patients who enroll can receive:
- Insightful tips and tools to help them along the way
- Supplemental injection training virtually or over the phone
- Financial assistance for eligible patients
- Assistance with insurance questions
- Assistance locating a specialty pharmacy that can dispense DUPIXENT
DUPIXENT can be administered at home or in the office.
DUPIXENT is an injectable medicine that is administered by subcutaneous injection. DUPIXENT is intended for use under the guidance of a healthcare provider. However, patients 12 years of age and older may self-inject DUPIXENT at home after receiving training in subcutaneous injection technique using the pre-filled syringe or pen. It is recommended that pediatric patients 12 to 17 years of age administer DUPIXENT under the supervision of an adult. In pediatric patients 6 to less than 12 years of age, DUPIXENT should be given by a caregiver.1
LEARN MORE ABOUT DOSAGESSevere asthma management by an allergist or a pulmonologist may involve:
- Evaluation of OCS use and asthma attack history and reconfirmation of asthma diagnosis
- Assessment of biomarkers of type 2 inflammation
- Allergy testing
- Pulmonary function tests
- Evaluation of coexisting T2 inflammatory diseases and degree of control
- Consideration of add-on biologic therapies
DUPIXENT provides eligible patients with access supportj-l
Overall, ~98% of commercially insured patients nationally are covered for DUPIXENT.7,j
Coverage varies by type and plan.
jMMIT Lives as of July 2022.
kEligible patients subject to program restrictions.
lApproval is not guaranteed. Program has an annual maximum of $13,000. THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed or restricted. DUPIXENT MyWay reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients' out-of-pocket costs. The program is intended to help patients afford DUPIXENT. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms. Additional terms and conditions apply.
Refer your appropriate asthma patients
to a specialist today
Partner with an asthma specialist to help
your patients. Use the Healthgrades®
tool
to easily find nearby
specialists.
Sanofi US and Regeneron neither endorse nor recommend any
particular physician, and
search
results do not include a
comprehensive list of doctors in your area.
